A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Bristol Myers buys into Janux’s ‘masked’ T cell engagers
Bristol Myers buys into Janux’s ‘masked’ T cell engagers
FDA lays out new path to speed development of multiple myeloma drugs
FDA lays out new path to speed development of multiple myeloma drugs
BioMarin vets form Mendra to ‘modernize’ rare disease drug development
BioMarin vets form Mendra to ‘modernize’ rare disease drug development
Corvus shares nearly triple on positive data for eczema pill
Corvus shares nearly triple on positive data for eczema pill
J&J eyes $100B in sales amid gains for cancer, immune drugs
J&J eyes $100B in sales amid gains for cancer, immune drugs
Valneva to withdraw Chikungunya vaccine from US amid safety woes
Valneva to withdraw Chikungunya vaccine from US amid safety woes
GSK to buy Rapt in $2.2B deal for food allergy drug
GSK to buy Rapt in $2.2B deal for food allergy drug
Moderna cancer vaccine holds up; IO Biotech considers a sale
Moderna cancer vaccine holds up; IO Biotech considers a sale
Kailera’s Ron Renaud on how a China-linked startup can compete in obesity
Kailera’s Ron Renaud on how a China-linked startup can compete in obesity
The patient retention crisis is happening before enrollment even begins
The patient retention crisis is happening before enrollment even begins
When every day counts: Building CRO partnerships on a foundation of trust, care and precision
When every day counts: Building CRO partnerships on a foundation of trust, care and precision
Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading
Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading
On biotech’s biggest stage, renewed excitement gets a stress test
On biotech’s biggest stage, renewed excitement gets a stress test
Trump unveils healthcare affordability plan
Trump unveils healthcare affordability plan
Tecvayli tops standard drugs in early multiple myeloma, J&J says
Tecvayli tops standard drugs in early multiple myeloma, J&J says
Oxford Biomedica confirms takeover talks with biotech investor EQT
Oxford Biomedica confirms takeover talks with biotech investor EQT
Boston Scientific to acquire Penumbra for $14.5B
Boston Scientific to acquire Penumbra for $14.5B
JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view
JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page